Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PLAU | P00749 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | MRGPRX4 | Q96LA9 | 5/20 | 0.48 |
| ▸ | BCL9 | O00512 | 1/20 | 0.45 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9623610 | 0.91 | LMNA (0.66) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL31500908 | 0.87 | TTR (0.55) | LMNAMAPK1HTTRAB9APLAU | |
| SCHEMBL25317057 | 0.87 | LMNA (0.60) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL18254560 | 0.85 | CREBBP (0.50) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL1470380 | 0.85 | LMNA (0.63) | LMNAMAPK1HTTRAB9ATHRA | |
| Bromide SCHEMBL31500912 | 0.85 | TTR (0.54) | LMNAMAPK1HTTRAB9APLAU | |
| SCHEMBL15067061 | 0.85 | LMNA (0.58) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL1749795 | 0.84 | THRA (0.62) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL9440011 | 0.84 | THRA (0.66) | LMNAMAPK1HTTRAB9ATHRA | |
| SCHEMBL9622934 | 0.84 | PKM (0.60) | LMNAMAPK1HTTRAB9APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | LMNA 1809/4885MAPK1 582/4885HTT 1827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.